Can a new vaccine stop a Lesser-Known bacterial threat?
NCT ID NCT07743008
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase 2 trial is testing an experimental vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections. Healthy adults aged 18 to 65 will be randomly assigned to receive either the vaccine or a placebo. The main goals are to assess the vaccine's safety and measure the immune response it triggers, which could indicate its potential to prevent Hia disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental vaccine against Haemophilus influenzae type a (Hia)
- What this could lead to
- If successful, this vaccine could help prevent serious Hia infections, potentially reducing the burden of this disease in vulnerable populations.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the vaccine may not prove effective or safe enough for wider use. Side effects like injection-site reactions or fever are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILUS INFLUENZAE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Canadian Center for Vaccinology
Halifax, Nova Scotia, Canada
-
Vaccine Study Centre of the McGill University Health Centre
Montreal, Quebec, Canada